Résultats comparatifs de la wedge résection versus duodénopancréatectomie céphalique pour tumeur stromale gastro intestinale du duodénum : à propos de deux cas et revue systématique

  • T. Merabti Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • T. Hadid Service d’Anesthésie Réanimation CLCC Draa Ben Khedda
  • N. Lallouti Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • M.B Ramoul Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • B. Lazizi Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • K.N Lardjane Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • R Kedjem. Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • A Djadjoua. Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • R. Bouzouagh. Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • D. Zeghdoud Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
  • C Bouzid Service de chirurgie oncologique, CLCC Draa Ben Khedda, Tizi Ouzou, Algerie.
Keywords: GIST duodénaux, wedge résection, duodénopancréatectomie céphalique, résection R0

Abstract

Introduction : Les tumeurs stromales gastro-intestinales (GIST) duodénales représentent une entité rare, ne constituant qu’environ 5 % de l’ensemble des GIST. Leur prise en charge chirurgicale demeure complexe en raison de la proximité avec les structures pancréatico-biliaires, soulevant le choix entre chirurgie conservatrice et duodénopancréatectomie céphalique (DPC).
observation : Nous rapportons deux cas illustratifs. Le premier concerne un homme de 65 ans présentant une masse duodénale de 2,5 cm traitée par résection cunéiforme, avec évolution favorable sans recours à un traitement adjuvant. Le second cas concerne une femme de 43 ans porteuse d’une GIST duodénale de 5,4 cm, traitée par DPC selon Whipple, compliquée d’une fistule pancréatique. L’examen histologique a conclu à une GIST à risque modéré, justifiant un traitement adjuvant par imatinib.
résultats : Ces observations soulignent l’importance d’adapter la stratégie chirurgicale à la taille, la localisation et au risque tumoral. La résection limitée constitue une approche sûre et efficace pour les lésions localisées, tandis que la DPC reste indiquée pour les formes volumineuses ou infiltrantes.
conclusion : Les données récentes de la littérature soutiennent la préservation d’organe et l’apport de la chirurgie mini-invasive et de la thérapie ciblée dans la réduction de la morbidité et l’amélioration de la qualité de vie.

Summary :

Introduction : Duodenal gastrointestinal stromal tumors (GISTs) constitute a rare entity, accounting for approximately 5% of all GISTs. Their surgical management remains challenging due to the close anatomical relationship with pancreatobiliary structures, raising the critical question between organ-preserving surgery and pancreaticoduodenectomy (Whipple procedure).

Case presentation : We report two illustrative cases. The first involved a 65-year-old man with a 2.5 cm duodenal mass successfully treated by wedge resection, with favorable postoperative outcomes and no need for adjuvant therapy. The second concerned a 43-year-old woman presenting with a 5.4 cm duodenal GIST, managed by Whipple resection complicated by a postoperative pancreatic fistula. Histopathological examination revealed an intermediate-risk GIST, warranting adjuvant imatinib therapy.

Results : These cases highlight the need to adapt surgical strategy according to tumor size, location, and risk classification. Limited resection represents a safe and effective option for localized lesions, whereas pancreaticoduodenectomy remains appropriate for large or infiltrative forms.

Conclusion : Recent literature supports organ-preserving strategies and underscores the contribution of minimally invasive surgery and targeted therapy in reducing postoperative morbidity and improving quality of life.

 

References

Références :
1. Joensuu H, Eriksson M, Sundström S, et al. Gastrointestinal stromal tumour. Lancet. 2013;382(9899):973-83. doi: 10.1016/S0140-6736(13)60106-3 [1]
2. Shen Z, Chen P, Du N, et al. Pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors: a systematic review and meta-analysis. BMC Surg. 2019;19:121. doi: 10.1186/s12893-019-0587-4 [2]
3. Casali, P G et al. “Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 33,1 (2022): 20-33. doi:10.1016/j.annonc.2021.09.005 [3]
4. Corless CL, Medina S, Dickinson BD, et al. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors: a mini-review. Front Oncol. 2024;14:1487467. doi: 10.3389/fonc.2024.1487467 [4]
5. Liang X, Yu H, Zhu LH, et al. Gastrointestinal stromal tumors of the duodenum: surgical management and survival results. World J Gastroenterol. 2013;19(36):6000-6010. doi: 10.3748/wjg.v19.i36.6000 [5]
6. Chen P, Song T, Mao D, et al. Limited Resection Versus Pancreaticoduodenectomy for Duodenal Gastrointestinal Stromal Tumors? Enucleation Interferes in the Debate: A European Multicenter Retrospective Cohort Study. Ann Surg Oncol. 2021;28(7):3764-3773. doi: 10.1245/s10434-02109862-7 [6]
7. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. Br J Surg. 2024;111(6):1527-1544. doi: 10.1093/bjs/znae125 [7]
8. Zhou YM, Zhang XF, Cai ZB, et al. Pancreaticoduodenectomy versus local resection in the treatment of gastrointestinal stromal tumors of the duodenum. World J Surg Oncol. 2013;11:1. doi: 10.1186/1477-7819-11-1 [8]
9. Wu L, Liu M, Lin X, et al. Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: a retrospective cohort study. BMC Surg. 2024;24:126. doi: 10.1186/s12893-024-02417-z [9]
10. Hotson TC, Groeschl R, Turley R, et al. Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-institutional Analysis. Ann Surg Oncol. 2012;19(11):3351-3360. doi: 10.1245/s10434-012-2551-8 [10]
11. Wu L, Liu M, Lin X, Wang C, Yang Y, Fang H, et al. Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: a retrospective cohort study. BMC Surg. 2024;24:126. [1]
12. Shen Z, Chen P, Du N, Khadaroo PA, Mao D, Gu L. Pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors: a systematic review and meta-analysis. BMC Surg. 2019;19(1):121. [2]
13. Vo TQ, Minh TP, Tran LC, Doan MT. Computed tomography on the 5th postoperative day helps distinguish grade C from grade B pancreatic fistula after pancreaticoduodenectomy for periampullary cancer. Formosan Journal of Surgery. 2024 Nov 1;57(6):232-7. [3]
14. Evaluation of the results of the modified Blumgart pancreatic-intestinal anastomosis technique according to Satoi in pancreaticoduodenectomy at Bach Mai Hospital. Vietnam J Sci Technol. 2024;62(2):1-12. [4]
15. Lim KT. Current surgical management of duodenal gastrointestinal stromal tumors. World J Gastrointest Surg. 2021;13(10):1166-1179. [5]
16. Risk stratification of clinically relevant delayed gastric emptying after pancreaticoduodenectomy. Hepatobiliary Pancreat Dis Int. 2023;22(4):465-472. [6]
17. Impact of Preoperative Biliary Stenting on Intestinal Dysfunction and Perioperative Complications After Pylorus-Preserving Pancreaticoduodenectomy. Medicina. 2025;61(3):391. [7]
18. Limited resection for duodenal gastrointestinal stromal tumors: Surgical management and clinical outcome. World J Gastrointest Surg. 2013;5(2):16-21. [8]
19. A systematic review and meta-analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors. World J Surg. 2024;48(5):1234-1245. [9]
20. Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST. Cancers. 2025;17(4):634. [10]
21. Practical Role of Mutation Analysis for Imatinib Treatment in Patients With Advanced Gastrointestinal Stromal Tumors: A Meta-Analysis. J Gastrointest Surg. 2013;17(11):1896-1910. [11]
22. Suto, Hirotaka et al. “Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With KIT Exon 11 W557_K558 Deletion.” In vivo (Athens, Greece) vol. 39,1 (2025): 532-538. doi:10.21873/invivo.13857. [12]
23. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients. Ann Surg Oncol. 2023;30(10):6314-6324. [13]
24. Optimal Laparoscopic Management and Oncological Outcomes of Gastrointestinal Stromal Tumors in Duodenum: Pancreaticoduodenectomy or Pancreas-Sparing Duodenectomy? J Gastrointest Surg. 2020;24(5):1165-1178. [14]
25. Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era. J Clin Med. 2023;12(14):4682. [15]
26. Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor. Sci Rep. 2023;13(1):12045. [16]
27. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. J Gastrointest Surg. 2018;22(9):1605-1617. [17
28. NovelPrognostic Nomogram for Recurrence-Free Survival of Patients With Primary Gastrointestinal Stromal Tumors After Surgical Resection: Combination of Prognostic Nutritional Index and Basic Variables. Nutrients. 2021;10(2):241. [18]
29. Risk factors for delayed gastric emptying after laparoscopic pancreaticoduodenectomy: a single-center experience of 1,000 cases. Zhonghua Yi Xue Za Zhi. 2023;103(32):2532-2541. [19]
30. Surgical Management of Postoperative Grade C Pancreatic Fistula following Pancreatoduodenectomy. World J Surg. 2022;46(3):542-553. [20]
31. Risk factors for exocrine pancreatic insufficiency after pancreatic surgery: a systematic review and meta-analysis. Nutrients. 2022;11(11):2798. [21]
32. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United European Gastroenterol J. 2024;12(9):1268-1326. [22]
33. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. World J Gastroenterol. 2019;25(10):1217-1232. [23]
34. Three-Year Observation of Glucose Metabolism After Pancreaticoduodenectomy: A SingleCenter Prospective Study in Japan. Pancreas. 2022;51(8):891-897. [24]
35. Impact of diabetes mellitus on morbidity and survival after pancreaticoduodenectomy for malignancy. Korean J Hepatobiliary Pancreat Surg. 2021;25(2):230-238. [25]
36. Surgical Approaches and Oncological Outcomes in the Management of Duodenal Gastrointestinal Stromal Tumors (GIST). J Clin Med. 2021;10(19):4459. [26]
37. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. J Gastric Cancer. 2016;16(2):76-89. [27]
38. Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines. Gastric Cancer. 2018;21(2):190-203. [28]
Published
2025-12-31
Section
case report